Related references
Note: Only part of the references are listed.Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia
Giuseppe Todeschini et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis
A. M. Evens et al.
ANNALS OF ONCOLOGY (2012)
RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma
Gaetano Corazzelli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis
J. A. Barnes et al.
ANNALS OF ONCOLOGY (2011)
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid
Jae H. Park et al.
BLOOD (2011)
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
Elias Campo et al.
BLOOD (2011)
Proportions of Kaposi Sarcoma, Selected Non-Hodgkin Lymphomas, and Cervical Cancer in the United States Occurring in Persons With AIDS, 1980-2007
Meredith S. Shiels et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions
Jennifer J. Turner et al.
BLOOD (2010)
AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?
Mercy Guech-Ongey et al.
BLOOD (2010)
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
Graham M. Mead et al.
BLOOD (2008)
Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study
Mary Gerrard et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma - Comparison of results in human immunodeficiency virus-infected and noninfected patients
Albert Oriol et al.
CANCER (2008)
Challenges in the recruitment of adolescents and young adults to cancer clinical trials
Megan E. Burke et al.
CANCER (2007)
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
DA Thomas et al.
CANCER (2006)
Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma
ES Wang et al.
CANCER (2003)
The Societe Francaise d'Oncologie Pediatrique LMB89 protocol:: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia
C Patte et al.
BLOOD (2001)
Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: A pediatric oncology group study
BH Pollock et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
